GleamWall
中文EN

CASIF CASI Pharmaceuticals, Inc. Annual reports only

Pharmaceutical Preparations · OTC · SEC CIK 1962738 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-15.8%
TTM net income YoY-45.6%
TTM EPS YoY-26.7%
Revenue 3-yr CAGR-1.8%
Net income 3-yr CAGR—

Margins

Gross margin39.1%
Operating margin-138.8%
Net margin-137.6%
FCF margin-103.2%
EBITDA margin-134.3%

Returns

ROE-301.8%
ROA-60.9%
ROIC (approx.)-435.9%
Asset turnover0.44x

Leverage & solvency

Liabilities / assets96.6%
Debt / equity0.00x
Current ratio1.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-15.6%
Payout ratio—
Capex / revenue0.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$20.71M$28.54M
Cost of revenue$10.64M$17.39M
Gross profit$10.08M$11.15M
R&D expense$6.31M$8.92M
SG&A expense$28.27M$23.58M
Operating income-$45.01M-$39.62M
Pretax income-$45.87M-$38.07M
Income tax—$0
Net income-$48.06M-$39.26M
EBITDA-$43.81M-$38.32M
EPS (basic)-2.59-2.56
EPS (diluted)-2.59-2.56
Weighted avg. shares (diluted)18.54M15.34M
Balance sheet
Cash & equivalents$5.63M$13.47M
Receivables$4.09M$15.35M
Inventory$1.60M$5.25M
Current assets$13.46M$39.58M
PP&E, net$6.97M$7.87M
Intangibles$221,000$238,000
Total assets$25.65M$53.67M
Current liabilities$49.67M$36.45M
Short-term debt$19.19M$18.39M
Total liabilities$62.93M$51.82M
Shareholders' equity-$37.28M$1.85M
Shares outstanding20.56M15.49M
Cash flow statement
Operating cash flow-$20.75M-$29.22M
Capital expenditure$16,000$223,000
Free cash flow-$20.77M-$29.45M
Investing cash flow$951,000$11.24M
Financing cash flow$11.25M$15.43M
Depreciation & amortization$1.20M$1.30M
Stock-based compensation$2.99M$1.31M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.